BioCentury
ARTICLE | Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

August 10, 2019 12:33 AM UTC

Nektar tumbles on bempegaldesleukin revelation
Nektar Therapeutics (NASDAQ:NKTR) fell $8.65 (29%) to close at $20.92 after reporting during its 2Q19 earnings call late Thursday that it had connected decreasing responses seen in a trial of bempegaldesleukin/Opdivo combination to a manufacturing issue (see "Nektar Links ‘Softening’ Response to Bempegaldesleukin to CMC Issues").

Novo beats on Ozempic, obesity drugs
Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported sales of diabetes drug Ozempic semaglutide were DKK2.33 billion ($349 million) for the quarter, beating analyst expectations of DKK1.84 billion. The company’s obesity segment notched DKK1.46 billion in sales, beating estimates of DKK1.27 billion. Revenues for the quarter totaled DKK30.04 billion, topping consensus estimates of DKK29.46 billion. Novo raised its 2019 sales growth forecast to 4-6% from 2-5% at constant exchange rates...